ong-term safety study by A1-PI
Phase 1
Completed
- Conditions
- AATD
- Registration Number
- JPRN-jRCT2080223139
- Lead Sponsor
- Grifols Japan K.K.
- Brief Summary
ong-term weekly intravenous infusions of 60 mg/kg Alpha-1 MP are generally safe and well-tolerated in Japanese patients with AATD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Main inclusion criteria:
Subjects who complete participation in another study (JapicCTI-No.163160)
Exclusion Criteria
Main exclusion criteria:
Subjects who are not enrolled in JapicCTI-No.163160
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method safety<br>Long-term Safety
- Secondary Outcome Measures
Name Time Method safety<br>Long-term safety